Role of serum calprotectin in identifying familial Mediterranean fever attacks
- PMID: 38478181
- DOI: 10.1007/s11845-024-03659-9
Role of serum calprotectin in identifying familial Mediterranean fever attacks
Abstract
Background/aim: The aim of the study was to evaluate serum calprotectin (CLP) levels in familial Mediterranean fever (FMF) patients and to investigate the utility of CLP in distinguishing patients with attack from patients without attack.
Material and method: FMF patients, rheumatoid arthritis (RA) patients, and healthy controls were included. Serum calprotectin levels were quantified utilizing the enzyme-linked immunosorbent assay (ELISA) method. Receiver operating characteristic (ROC) curve analysis was used to identify the cut-off value of serum CLP level to differentiate FMF patients with attack from those without. Logistic regression analysis was performed to identify predictors.
Results: Significant differences were observed among the three groups concerning white blood cell (WBC), neutrophil, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum CLP levels (p = 0.003, p = 0.004, p < 0.001, p < 0.001, and p = 0.002, respectively). Higher ESR, CRP, and serum CLP levels were observed in FMF patients with attacks than those without (all, p < 0.001). Serum CLP was significantly higher in RA patients than in FMF patients in remission (p < 0.001). ROC analysis identified a threshold CLP concentration in FMF with an attack to be 47.1 pg/mL (83.3% sensitivity, 60.6% specificity, AUC = 0.74, 95% CI = 0.63-0.85, p < 0.001). In univariate logistic regression analysis, CLP (β = 1.045, 95% CI = 1.017-1.073, p = 0.001) was predictive of FMF patients experiencing an attack.
Conclusion: Serum CLP proves to be as productive as ESR in illustrating inflammation and demonstrating the existence of attacks in FMF patients.
Keywords: Acute phase reactants; Attacks; Calprotectin; Familial Mediterranean fever; Rheumatoid arthritis.
© 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.
Similar articles
-
Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?J Korean Med Sci. 2020 Mar 16;35(10):e63. doi: 10.3346/jkms.2020.35.e63. J Korean Med Sci. 2020. PMID: 32174062 Free PMC article.
-
Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.Clin Rheumatol. 2020 Jan;39(1):249-253. doi: 10.1007/s10067-019-04765-1. Epub 2019 Sep 4. Clin Rheumatol. 2020. PMID: 31485845
-
Evaluation of serum CXC chemokine ligand 16 (CXCL16) as a novel inflammatory bio- marker or familial Mediterranean fever disease.Turk J Med Sci. 2021 Apr 30;51(2):813-818. doi: 10.3906/sag-2010-64. Turk J Med Sci. 2021. PMID: 33306334 Free PMC article.
-
The Value of Serum Amyloid A Levels in Familial Mediterranean Fever to Identify Occult Inflammation During Asymptomatic Periods.J Clin Rheumatol. 2021 Jan 1;27(1):1-4. doi: 10.1097/RHU.0000000000001134. J Clin Rheumatol. 2021. PMID: 31524848
-
Interventions for reducing inflammation in familial Mediterranean fever.Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD010893. doi: 10.1002/14651858.CD010893.pub4. Cochrane Database Syst Rev. 2022. PMID: 35349164 Free PMC article. Review.
References
-
- Gucenmez OA, Kume T, Makay B et al (2018) Role of fecal calprotectin in the assessment of intestinal inflammation in children with familial Mediterranean fever. Int J Rheum Dis 21:1844–1848. https://doi.org/10.1111/1756-185X.13396 - DOI - PubMed
-
- Lachmann H, Şengül B, Yavuzşen TU et al (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology 45(6):746–750. https://doi.org/10.1093/rheumatology/kei279 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous